Therapy for recurrent respiratory papillomatosis

Antiviral Therapy

Volumn 7, Issue 1, 2002, Pages 1-9

  Auborn, Karen J ^a,b  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b BoasMarks Biomed Sci Res Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ACICLOVIR; ANTACID AGENT; CIDOFOVIR; CIMETIDINE; DIINDOLYLMETHANE; INTERFERON; ISOTRETINOIN; MUMPS VACCINE; PLACEBO; RETINOIC ACID; RIBAVIRIN; UNCLASSIFIED DRUG;

ANEMIA; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HUMAN; LARYNX TUMOR; LEUKOPENIA; META ANALYSIS; NEPHROTOXICITY; PAPILLOMATOSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT; TUMOR GROWTH; UTERINE CERVIX TUMOR; VIROGENESIS; VOCAL CORD; WART VIRUS;

CYTOSINE; HUMANS; INTERFERONS; LARYNGEAL NEOPLASMS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; ORGANOPHOSPHORUS COMPOUNDS; PAPILLOMA; PAPILLOMAVIRIDAE; PHOSPHONIC ACIDS; PHOTOCHEMOTHERAPY; VOCAL CORDS;

EID: 0036523573     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Gissmann L, Diehl V, Schultz-Coulon HJ & zur Hausen H. Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. Journal of Virology 1982; 44:393-400.
2. Mounts P, Shah KV & Kashima H. Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx. Proceedings of the National Academy of Sciences USA 1982; 79:5425-5429.
3. Gissmann L, Wolnik L, Ikenberg H, Koldovsk U, Schnurch HG & zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proceedings of the National Academy of Sciences USA 1983; 80:560-563.
4. Kreider JW, Howett MK, Lill NL, Bartlett GL, Zaino RJ, Sedlacek TV & Mortel R. In vivo transformation of human skin with human papillomavirus type 11 from condylomata acuminata. Journal of Virology 1986; 59:369-376.
5. Kreider JW, Howett MK, Stoler MH, Zaino RJ & Welsh P. Susceptibility of various human tissues to transformation in vivo with human papillomavirus type 11. International Journal of Cancer 1987; 39:459-465.
6. Arndt O, Johannes A, Zeise K & Brock J. High-risk HPV types in oral and laryngeal papilloma and leukoplakia. Laryngo-Rhino-Otologie 1997; 76:142-149.
7. Steinberg BM, Topp WC, Schneider PS & Abramson AL. Laryngeal papillomavirus infection during clinical remission. New England Journal of Medicine 1983; 308:1261-1264.
8. Bauman NM & Smith RJ. Recurrent respiratory papillomatosis. Pediatric Clinics of North America 1996; 43:1385-1401.
9. Kashima HK, Mounts P & Shah K. Recurrent respiratory papillomatosis. Obstetrics and Gynecology Clinics of North America 1996; 23:699-706.
10. Derkay CS, Rimell FL & Thompson JW. Recurrent respiratory papillomatosis. Head & Neck 1998; 20:418-424.
11. Armstrong LR & Derkay CS. Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Archives of Otolaryngology - Head & Neck Surgery 1999; 125:743-748.
12. Lindeberg H & Elbrond O. Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965-1984. Clinical Otolaryngology and Allied Sciences 1990; 15:125-131.
13. Kashima HK, Shah F, Lyles A, Glackin R, Muhammad N, Turner L, Van Zandt S, Whitt S & Shah K. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope 1992; 102:9-13.
14. Shah KV, Stern WF, Shah FK, Bishai D & Kashima HK. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatric Infectious Disease Journal 1998; 17:372-376.
15. Brandsma JL & Abramson AL. Association of papillomavirus with cancers of the head and neck. Archives of Otolaryngology - Head & Neck Surgery 1989; 115:621-625.
16. Kashima H, Mounts P, Leventhal B & Hruban RH. Sites of predilection in recurrent respiratory papillomatosis. Annals of Otology, Rhinology & Laryngology 1993; 102:580-583.
17. Abramson AL, Steinberg BM & Winkler B. Laryngeal papillomatosis: clinical, histopathologic and molecular studies. Laryngoscope 1987; 97:678-685.
18. Zehnder PR Jr & Lyons GD. Carcinoma and Juvenile papillomatosis. Annals of Otology, Rhinology & Laryngology 1975; 84:614-618.
19. Solomon D, Smith RR, Kashima HK & Leventhal BG. Malignant transformation in non-irradiated recurrent respiratory papillomatosis. Laryngoscope 1985; 95:900-904.
20. Hartley C, Hamilton J, Birzgalis AR & Farrington WT. Recurrent respiratory papillomatosis - the Manchester experience, 1974-1992. Journal of Laryngology & Otology 1994; 108:226-229.
21. Zhang N & Jia S. Malignant changes in laryngeal papilloma with 13 case reports. Journal of Clinical Otorhinolaryngology 1997; 11:54-55.
22. Helmrich G, Stubbs TM & Stoerker J. Fatal maternal laryngeal papillomatosis in pregnancy: a case report. American Journal of Obstetrics and Gynecology 1992; 166:524-525,
23. Simpson GT II & Strong MS. Recurrent respiratory papillomatosis: the role of the carbon dioxide laser. Otolaryngologic Clinics of North America 1983; 16:887-894.
24. Shikowitz MJ, Abramson AL & Liberatore L. Endolaryngeal jet ventilation: a 10-year review. Laryngoscope 1990; 101:455-461.
25. Kashima HK, Kessis T, Mounts P & Shah K. Polymerase chain reaction identification of human papillomavirus DNA in CO, laser plume from recurrent respiratory papillomatosis. Archives of Otolaryngology - Head & Neck Surgery 1991; 104:191-195.
26. Ponten J & Guo Z. Precancer of the human cervix. Cancer Surveys 1998; 32:201-229.
27. Cox JT. Epidemiology of cervical intraepithelial neoplasia: the role of human papillomavirus. Clinical Obstetrics & Gynaecology 1995; 9:1-37.
28. Steinberg BM & Abramson AL. Laryngeal papillomas. Clinics in Dermatology 1985; 3:30-38.
29. Essman EJ & Abramson A. Estrogen binding sites on membranes from human laryngeal papilloma. International Journal of Cancer 1984; 33:33-36.
30. Newfield L, Goldsmith A, Bradlow HL & Auborn K. Estrogen metabolism and human papillomavirus-induced tumors of the larynx: chemo-prophylaxis with indole-3-carbinol. Anticancer Research 1993; 13:337-341.
31. Auborn KJ, Woodworth C, DiPaolo JA & Bradlow HL. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. International Journal of Cancer 1991; 49:867-869.
32. Yuan F, Chen DZ, Liu K, Sepkovic DW, Bradlow HL & Auborn K. Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. Anticancer Research 1999; 19:1673-1680.
33. Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Research 1998; 58:2269-2277.
34. Coll DA, Rosen CA, Auborn K, Potsic WP & Bradlow HL. Treatment of recurrent respiratory papillomatosis with indole-3-carbinol. American Journal of Otolaryngology 1997; 18:283-285.
35. Auborn K, Abramson A, Bradlow HL, Sepkovic D & Mullooly V. Estrogen metabolism and laryngeal papillomatosis: a pilot study on dietary prevention. Anticancer Research 1998; 18:4569-4573.
36. Rosen CA, Woodson GE, Thompson JW, Hengesteg AP & Bradlow HL. Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Archives of Otolaryngology - Head & Neck Surgery 1998; 118:810-815.
37. Cover CM, Hsieh SJ, Tran SH, Hallden G, Kim GS, Bjeldanes LF & Firestone GL. Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. Journal of Biological Chemistry 1998; 273:3838-3847.
38. Ge X, Fares FA & Yannai S. Induction of apoptosis in MCF-7 cells by indol-3-carbinol is independent of p53 and bax. Anticancer Research 1999; 19:3199-3203.
39. Thomas M, Matlashewski G, Pim D & Banks L. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene 1996; 13:265-273.
40. Shertzer HG, Berger ML & Tabor MW. Intervention in free radical mediated hepatotoxicity and lipid peroxidation by indole-3-carbinol, Biochemical Pharmacology 1988; 37:333-338.
41. Arnao MB, Sanchez-Bravo J & Acosta M. Indole-3-carbinol as a scavenger of free radicals. Biochemistry and Molecular Biology International 1996; 39:1125-1134.
42. Manson MM, Ball HW, Barrett MC, Clark HL, Judah DJ, Williamson G & Neal GE. Mechanism of action of dietary chemoprotective agents in rat liver: induction of phase I and II drug metabolizing enzymes and aflatoxin B1 metabolism. Carcinogenesis 1997; 18:1729-1738.
43. Safe SH. Environmental and dietary estrogens and human health: is there a problem? Environmental Health Perspectives 1995; 103:346-351.
44. Zhu BT & Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998; 19:1-27.
45. Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, Mayeaux, EJ, Tucker A, Turbat-Herrera EA & Mathis JM. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecologic Oncology 2000; 78:123-129.
46. Kashima H, Leventhal B, Clark K, Cohen S, Dedo H, Donovan D, Fearon B, Gardiner L, Goepfert H, Lusk R, McCabe BF, Mounts P, Muntz H, Richardson M, Singleton G, Weck P, Whisnant J, Wold D & Yonkers A. Interferon alfa-n1 (Wellferon) in juvenile onset recurrent respiratory papillomatosis: results of a randomized study in twelve collaborative institutions. Laryngoscope 1988; 98:334-340.
47. Mullooly VM, Abramson AL, Steinberg BM & Horowitz MS. Clinical effects of alpha-interferon dose variation on laryngeal papillomas. Laryngoscope 1988; 98:1324-1329.
48. Leventhal BG, Kashima HK, Mounts P, Thurmond L, Chapman S, Buckley S & Wold D. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1. Papilloma Study Group. New England Journal of Medicine 1991; 325:613-617.
49. Ingimarsson S, Cantell K & Strander H. Side effects of long-term treatment with human leukocyte interferon. Journal of Infectious Diseases 1979; 140:560-563.
50. Shikowitz MJ, Abramson AL, Freeman K, Steinberg BM & Nouri M. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope 1998; 108:962-967.
51. Lofgren LA, Ronn AM, Abramson AL, Shikowitz MJ, Nouri M, Lee CJ, Batti J & Steinberg BM. Photodynamic therapy using m-tetra(hydroxyphenyl) chlorin. An animal model. Archives of Otolaryngology - Head & Neck Surgery 1994; 120:1355-1362.
52. Mullooly VM, Abramson AL & Shikowitz MJ. Dihematoporphyrin ether-induced photosensitivity in laryngeal papilloma patients. Lasers in Surgery and Medicine 1990; 10:349-356.
53. De Clercq E, Andrei G, Balzarini J, Hatse S, Liekens S, Naesens L, Neyts J & Snoeck R. Antitumor potential of acyclic nucleoside phosphonates. Nucleosides & Nucleotides 1999; 18:759-771.
54. Christensen ND, Pickel MD, Budgeon LR & Kreider JW. In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas. Antiviral Research 1999; 43:1198-1205.
55. Ho ES, Lin DC, Mendel DB & Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. Journal of the American Society of Nephrology 2000; 11:383-393.
56. Snoeck R, Wellens W, Desloovere C, Van Ranst M, Naesens L, De Clercq E & Feenstra L. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxy propyl)cytosine]. Journal of Medical Virology 1998; 54:219-225.
57. Pransky SM, Brewster DF, Magit AE & Kearns DB. Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillo matosis. Archives of Otolaryngology - Head & Neck Surgery 2000; 126:1239-1243.
58. Wilson WR, Hashemiyoon R & Hawrych A. Intralesional cidofovir for recurrent laryngeal papillomas: preliminary Report. Ear, Nose & Throat Journal 2000; 79:236-238, 240.
59. Dancey DR, Chamberlain DW, Krajden M, Palefsky J, lberti PW & Downey GP. Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir case report and review of the literature. Chest 2000; 118:1210-1214.
60. Snoeck R, Bossens M, Parent D, Delaere B, Degreef H, Van Ranst M, Noel JC, Wulfsohn MS, Rooney JF, Jaffe HS & De Clercq E. Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection. Clinical Infectious Diseases 2000; 33:597-602.
61. Zerr DM & Frenkel LM. Advances in antiviral therapy. Current Opinion in Pediatrics 1999; 11:21-27.
62. Kiroglu M, Cetik F, Soylu L, Abedi A, Aydogan B, Akcali C, Kiroglu F & Ozsahinoglu C. Acyclovir in the treatment of recurrent respiratory papillomatosis: a preliminary report. American Journal of Otolaryngology 1994; 15:212-214.
63. Endres DR, Bauman NM, Burke D & Smith RJ. Acyclovir in the treatment of recurrent respiratory papillomatosis. A pilot study. Annals of Otology, Rhinology & Laryngology 1994; 103:301-305.
64. Bollag W. Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1,25-dihydroxyvitamin D3, and analogs. Journal of Cellular Biochemistry 1994; 56:427-435.
65. Taylor-Cooley LD & Donovan DT. Isotretinoin therapy for recurrent respiratory papillomatosis. Archives of Otolaryngology - Head & Neck Surgery 1994; 120:405-409.
66. Alberts DS, Coulthard SW & Meyskens FL Jr. Regression of aggressive laryngeal papillomatosis with 13-cis-retinoic acid (accutane). Journal of Biological Response Modifiers 1986; 5:124-128.
67. Eicher SA, Taylor-Cooley LD & Donovan DT. Isotretinoin therapy for recurrent respiratory papillomatosis. Archives of Otolaryngology - Head & Neck Surgery 1994; 120:405-409.
68. Bell R, Hong WK, Itri LM, McDonald G & Strong MS. The use of cis-retinoic acid in recurrent respiratory papillomatosis of the larynx: a randomized pilot study. American Journal of Otolaryngology 1988; 9:161-164.
69. McHutchison JG & Younossi Z. Treatment strategies for hepatitis C: making the best of limited options. Cleveland Clinic Journal of Medicine 2000; 67:476-480.
70. Falsey AR & Walsh EE. Respiratory syncytial virus infection in adults. Clinical Microbiology Reviews 2000; 13:371-384.
71. McGlennen RC, Adams GL, Lewis CM, Faras AJ & Ostrow RS. Pilot trial of ribavirin for the treatment of laryngeal papillomatosis. Head & Neck 1993; 15:504-512, discussion 512-513.
72. Griswold DE, Alessi S, Badger AM, Poste G & Hanna N. Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. Journal of Immunology 1984; 132:3054-3057.
73. Glass AT & Solomon BA. Cimetidine therapy for recalcitrant warts in adults. Archives of Dermatology 1996; 132:680-682.
74. Gooptu C, Higgins CR & James MP. Treatment of viral warts with cimetidine: an open-label study. Clinical and Experimental Dermatology 2000; 25:183-185.
75. Harcourt JP, Worley G & Leighton SE. Cimetidine treatment for recurrent respiratory papillomatosis. International Journal of Pediatric Otorhinolaryngology 1999; 51:109-113.
76. Yilmaz E, Alpsoy E & Basaran E. Cimetidine therapy for warts: a placebo-controlled, double-blind study. Journal of the American Academy of Dermatology 1996; 34:1005-1007.
77. Jochmus I, Schafer K, Faath S, Muller M & Gissmann L. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Archives of Medical Research 1999; 30:269-274.
78. Ling M, Kanayama M, Roden R & Wu T. Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. Journal of Biomedical Science 2000; 7:341-356.
79. Schiller JT & Hidesheim A. Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. Journal of Clinical Virology 2000; 19:67-74.
80. Rose RC, Reichman RC & Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. Journal of General Virology 1994; 75:2075-2079.
81. Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, Hurni WM, Joyce JG, Lehman ED, Markus HZ, Neeper MP, Schultz LD, Shaw AR & Jansen KU. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African monkeys immunized with HPV-11 virus-like particles expressed in yeast. Journal of Infectious Diseases 1997; 176:1141-1145.
82. Christensen ND, Reed CA, Cladel NM, Han R & Kreider JW. Immunization with virus like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. Journal of Virology 1996; 70:960-965.
83. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J & Reichman RC. A phase I study of recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. Journal of Infectious Diseases 2001; 183:1485-1493.
84. Thompson HS, Davies ML, Holding FP, Fallon RE, Mann AE, O'Neill T & Roberts JS. Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts, Vaccine 1999; 17:40-49.
85. Lacey CJ, Thompson HS, Monteiro EF, O'Neill T, Davies ML, Holding FP, Fallon RE & Roberts JS. Phase IIa safety and immunogenicity of a therapeutic vaccine, TAGW, in persons with genital warts. Journal of Infectious Diseases 1999; 179:612-618.